Group B Streptococcus Market Infographics

Group B Streptococcus Market

A typical bacterium that is frequently seen in the intestines or lower genital tract is group B strep (streptococcus). In healthy individuals, the bacterium is mostly harmless; but, in neonates, it can result in the deadly sickness known as GBS.

Group B Streptococcus Epidemiology Insights (2022)

• The Total Group B Streptococcus incident cases in the 7MM - ~227K cases in 2022
• EU4 and the UK contributed ~20% of incident cases
• Nearly 2 million pregnant women were estimated to have Group B Streptococcus colonization
• Invasive type account for 22% of incident cases

Group B Streptococcus Epidemiology Segmentation in the 7MM from 2019 to 2040

• Total Incident Cases
• Type-specific Incident Cases
• Age-specific Incident Cases of GBS by types
• Number of Cases of GBS Colonization

Group B Streptococcus Market Insight (2022)

• The Group B Streptococcus Market size in the 7MM was valued ~USD 194 million in 2022
• The United States captured the largest market size for Group B Streptococcus among the 7MM regions

Group B Streptococcus Emerging Drugs and Key Companies

• GBS-NN/NN2: Minervax ApS
• GBS 6 (PF-06760805): Pfizer, and others